N@N

Salveen Richter Maintained (ACAD) at Hold with Decreased Target to $24 on, Mar 7th, 2022

Salveen Richter of Goldman Sachs, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Decreased Target from $27 to $24 on, Mar 7th, 2022.

Salveen has made no other calls on ACAD in the last 4 months.

There are 10 other peers that have a rating on ACAD. Out of the 10 peers that are also analyzing ACAD, 6 agree with Salveen's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Vamil Divan of "Mizuho" Maintained at Hold with Decreased Target to $28 on, Thursday, March 3rd, 2022
• Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $31 on, Tuesday, March 1st, 2022
• Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Increased Target to $30 on, Wednesday, December 22nd, 2021
• Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Held Target at $28 on, Tuesday, December 21st, 2021
• Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $23 on, Thursday, December 9th, 2021
• Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $24 on, Tuesday, December 7th, 2021

These are the ratings of the 4 analyists that currently disagree with Salveen

---

• Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $35 on, Tuesday, March 1st, 2022
• Andrew Fein of "HC Wainwright & Co." Upgraded from Hold to Strong Buy and Increased Target to $36 on, Wednesday, February 9th, 2022
• Neena Bitritto-Garg of "Citigroup" Upgraded from Hold to Strong Buy and Held Target at $30 on, Wednesday, January 5th, 2022
• Gregory Renza of "RBC Capital" Maintained at Buy with Increased Target to $34 on, Tuesday, December 21st, 2021

Contributing Sources

---